Evidence map›Paper›PMID 36892280›Full record

ArticleAntimicrobial agents and chemotherapy2023

Development of Nanobodies as Theranostic Agents against CMY-2-Like Class C β-Lactamases.

Frédéric Cawez, Paola Sandra Mercuri, Francisco Javier Morales-Yãnez, Rita Maalouf, Marylène Vandevenne, Frederic Kerff, Virginie Guérin, Jacques Mainil, Damien Thiry, Marc Saulmont and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Frédéric CawezInBioS, Center for Protein Engineering, Biological Macromolecules, Department of Life Sciences, University of Liège, Liège, Belgium.
Paola Sandra MercuriInBioS, Center for Protein Engineering, Biological Macromolecules, Department of Life Sciences, University of Liège, Liège, Belgium.
Francisco Javier Morales-YãnezInBioS, Center for Protein Engineering, NEPTUNS, Department of Life Sciences, University of Liège, Liège, Belgium.
Rita MaaloufInBioS, Center for Protein Engineering, NEPTUNS, Department of Life Sciences, University of Liège, Liège, Belgium.
Marylène VandevenneInBios, Center for Protein Engineering, ROBOTEIN, Department of Life Sciences, University of Liège, Liège, Belgium.
Frederic KerffInBioS, Center for Protein Engineering, Department of Life Sciences, University of Liège, Liège, Belgium.
Virginie GuérinBacteriology, FARAH and Faculty of Veterinary Medicine, Department of Infectious and Parasitic Diseases, University of Liège, Liège, Belgium.
Jacques MainilBacteriology, FARAH and Faculty of Veterinary Medicine, Department of Infectious and Parasitic Diseases, University of Liège, Liège, Belgium.ORCID 0000-0001-8520-0834
Damien ThiryBacteriology, FARAH and Faculty of Veterinary Medicine, Department of Infectious and Parasitic Diseases, University of Liège, Liège, Belgium.ORCID 0000-0002-5161-7364
Marc SaulmontRegional Animal Health and Identification Association (ARSIA), Ciney, Belgium.
Alain VanderplasschenALPANANO, Center for Protein Engineering & FARAH, University of Liège, Liège, Belgium.
Pierre LafayeInstitut Pasteur, Université Paris Cité, CNRS UMR 328, Paris, France.
Gabriel AyméInstitut Pasteur, Université Paris Cité, CNRS UMR 328, Paris, France.
Pierre BogaertsNational Reference Center for Antibiotic-Resistant Gram-Negative Bacilli, Department of Clinical Microbiology, CHU UCL Namur, Yvoir, Belgium.ORCID 0000-0002-4016-3707
Mireille DumoulinInBioS, Center for Protein Engineering, NEPTUNS, Department of Life Sciences, University of Liège, Liège, Belgium.
Moreno GalleniInBioS, Center for Protein Engineering, Biological Macromolecules, Department of Life Sciences, University of Liège, Liège, Belgium.ORCID 0000-0003-0992-0391
University of Liège · BECentre National de la Recherche Scientifique · FRCHU Dinant Godinne UCL Namur · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Three soluble single-domain fragments derived from the unique variable region of camelid heavy-chain antibodies (VHHs) against the CMY-2 β-lactamase behaved as inhibitors. The structure of the complex VHH cAb

Indexed as

Single-Domain AntibodiesAnimalsAntibodiesbeta-Lactamase Inhibitorsbeta-LactamasesEpitopesPenicillinsPrecision MedicineRabbitsAntibodiesbeta-Lactamase Inhibitorsbeta-LactamasesEpitopesPenicillinsSingle-Domain Antibodiesantibiotic resistanceclass C beta-lactamaseCMY-2 β-lactamasenanobodiesnew antibiotic scaffoldparatopesstructural biology

Identifiers

PMID36892280
PMCPMC10112224
OpenAlexW4323653301

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.